FIRST Trial: Lenalidomide/Dexamethasone versus Melphalan/Prednisone/Thalidomide in Newly Diagnosed Multiple Myeloma
CME INFORMATION

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unprecedented and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and data sets to consider but they are also severely restricted in their ability to review and interrogate the raw findings.

To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets on up-front and maintenance therapeutic options in the treatment of multiple myeloma (MM) from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts may be applied to routine clinical care. This activity will assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES

• Appraise recent clinical research findings on the efficacy and safety of lenalidomide in combination with low-dose dexamethasone (Rd) as an up-front therapeutic option for elderly patients with newly diagnosed MM, and consider this information for the treatment of patients.
• Compare and contrast the benefits and risks of bortezomib/melphalan/prednisone (VMP) and Rd for elderly patients with newly diagnosed MM when administered in a sequential versus an alternating manner.
• Assess the efficacy and safety of therapeutic regimens containing an alkylating agent versus those that do not for elderly, transplant-ineligible patients with newly diagnosed MM.
• Analyze the extended and updated results from the Phase III HOVON-65/GMMG-HD4 trial of bortezomib during induction and maintenance therapy for newly diagnosed MM, including outcomes of patients with renal failure.
• Evaluate the updated patient survival outcomes from the IFM 2005-02 study and the role of lenalidomide maintenance therapy after first-line autologous stem cell transplantation in MM.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCASH2014/1/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Director of Translational Research, B-Cell Malignancy Program
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Advisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Sanofi.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/ or investigational uses of agents that are not indicated by
the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Seattle Genetics and Spectrum Pharmaceuticals Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: January 2014
Expiration date: January 2015
The revolution in myeloma therapy engendered by the development of proteasome inhibitors and immune modulatory drugs has not only changed the natural history of the disease but also has led some investigators to adopt a “more is better” treatment goal whereby efforts are made at diagnosis to maximally drive down the tumor burden and keep it suppressed for as long as possible. Dr Sagar Lonial is among the champions of this concept, and last week I chatted with him to further clarify his vision of this paradigm and better understand how it applies to evolving clinical research, especially new data emerging at ASH.

The fundamental idea behind this strategy is perhaps not that much different than what has been hypothesized for many cancers in the past. As depicted by the innovative “iceberg” graphic (see below) that Sagar has been using in many of his recent presentations, the goal is either a diffuse large B-cell lymphoma-like cure or a much longer duration of freedom from disease progression.
Assays to assess MRD are critical to this type of clinical research, and interestingly, Dr Lonial believes that the approach may be far less relevant in the relapsed/refractory setting, where many more mutant tumor clones have developed. The concept of prolonged disease suppression with some type of maintenance is also part of this strategy, and like a number of investigators Sagar often uses a variation of RVD maintenance, particularly in patients with higher-risk tumors.

Many oncologists — myself included — carry a hard-learned skepticism of the “more is better” paradigm from prior research in other tumors, including metastatic breast cancer, where a classic ECOG trial run by Dr George Sledge demonstrated the same survival with combination chemotherapy versus sequential single agents, and an important and vocal segment of myeloma investigators — particularly Dr S Vincent Rajkumar and his Mayo Clinic colleagues — have supported less intensive and better tolerated treatment choices in patients at standard risk. Both groups are committed to cure as a goal, but there is disagreement about what this all means to current practice, and even Sagar believes that with the available therapies a very small fraction of patients might be cured, even functionally, and he is particularly focused on patients with MRD negativity by new flow cytometry techniques along with PET scan normalization.

At the last ASCO meeting, Dr Lonial co-chaired the oral myeloma session and discussed several major up-front trials within the context of the iceberg model. We found his take on the issue to be quite provocative and as such attempted to recreate the format for the first issue of our annual post-ASH roundup. Here is his bottom line on the most noteworthy related oral papers from New Orleans mixed with Dr Lonial’s perspectives:

1. **FIRST trial (Phase III): MPT versus 18 months of lenalidomide/low-dose dexamethasone versus continuous Rd until disease progression in transplant-ineligible patients**

Perhaps the most visible myeloma story out of ASH was this largely European trial that was afforded plenary status because in many parts of the world (unlike the US) where MPT is now utilized, this study will likely establish a new standard treatment as these data demonstrate superior PFS and OS in favor of continuous Rd versus MPT. However, perhaps even more relevant was the 38% statistically significant improvement in time to progression (32.5 versus 21.9 months) for continuous Rd as opposed to 18 months, though it may be too early to evaluate OS. This long-term treatment strategy is in keeping with (and may ultimately provide support for) Dr Lonial’s notion to proactively attempt to delay disease progression.

2. **Other trials of up-front management**

Not surprisingly, Dr Antonio Palumbo was again on stage at ASH presenting yet another Phase III trial of up-front treatment, this time evaluating Rd versus MPR versus
cyclophosphamide/prednisone/lenalidomide (CyPR) in elderly patients not eligible for transplant. Building off the FIRST trial, all 3 arms of this effort yielded comparable disease-related outcomes in terms of PFS and overall response rates. Of note, patients receiving melphalan experienced more treatment-related toxicity than those receiving cyclophosphamide, and Dr Lonial sees this as one more reason that in myeloma the end may be near for melphalan.

Another important up-front trial — **HOVON-65/GMMG-HD4** — reported more follow-up at ASH. This study, which had previously demonstrated an advantage to bortezomib with doxorubicin/dex induction therapy followed by bortezomib maintenance versus vincristine with doxorubicin/dex followed by thalidomide maintenance, continues to yield a PFS and OS benefit for the bortezomib-based regimen, and the update provides further support for the use of this proteasome inhibitor in patients with renal failure and adverse risk factors. The study used a bortezomib maintenance schedule of 1 dose every other week for 2 years, but Dr Lonial notes that subcutaneous maintenance bortezomib may be even more patient friendly, and oral proteasome inhibitors such as ixazomib and oprozomib might further facilitate this strategy.

Finally, a paper by **Mateos et al** investigated the novel induction strategy of alternating Rd with VMP in elderly patients. Although Dr Mateos and her colleagues conclude that the alternating scheme is superior in efficacy versus the sequential approach, it is difficult to compare this regimen to the 3- and 4-drug combinations currently used in practice. In keeping with his intent to achieve rapid and deep responses even in older patients (with tolerable regimens), Dr Lonial favors the combination approach.

### 3. More data on lenalidomide maintenance

Of the 3 major Phase III trials of len maintenance, two — CALGB-100104 and the Italian MM-015 study — have demonstrated a survival benefit, and this led to a major shift in US practice. However, the **third study** from the French IFM group (IFM 2005-02), which was updated at ASH, continues to show a substantial PFS benefit without improvement in OS. In discussing this data set, Dr Lonial noted that part of this discrepancy may be related to the IFM 2005-02 trial’s design, in which all patients received 2 months of post-transplant lenalidomide consolidation, including those randomly assigned to “no maintenance.” Another critical difference is that the IFM stopped len maintenance treatment at 2 years as opposed to indefinite therapy until disease progression/toxicity in the other 2 studies.

Also at ASH we saw findings from a **meta-analysis** of lenalidomide maintenance, demonstrating a PFS and OS benefit. However, Dr Lonial found it difficult to dissect out the relevance of this data set because it included patients who did and did not receive a transplant. The study did, however, provide some additional insight about the incidence of second primary cancers, which to this point appears to be mainly a modest risk of hematologic neoplasms, including AML and MDS.
Although the “more is better” investigators have focused on current regimens with approved agents, it is likely that completely different classes of drugs will be required to melt away substantially more of the iceberg, and in another myeloma issue in this series we will attempt to pick out the agents farthest along in this desperate race, including monoclonal antibodies and filanesib — a fascinating kinesin spindle protein inhibitor reported at ASH by Dr Lonial’s group to cause responses (as a single agent and with low-dose dex) in patients refractory to conventional agents. Next on this series, an ASH CML update including the current status of ponatinib.

Neil Love, MD
Research To Practice
Miami, Florida
FIRST Trial: Lenalidomide/Dexamethasone versus Melphalan/Prednisone/Thalidomide in Newly Diagnosed Multiple Myeloma

Presentation discussed in this issue


Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Sagar Lonial, MD (1/22/14)

Initial Phase 3 Results of the First (Frontline Investigation of Lenalidomide + Dexamethasone versus Standard Thalidomide) Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Stem Cell Transplantation (SCT)

Facon T et al.
Proc ASH 2013;Abstract 2.
Background

- Melphalan/prednisone/thalidomide (MPT) is a standard therapy for patients with newly diagnosed multiple myeloma (NDMM).
  - MPT demonstrated a statistically significant advantage in overall survival (OS) and progression-free survival (PFS) compared to MP (Blood 2011;118(5):1239).
- The combination of lenalidomide (R) with low-dose dexamethasone increased OS with reduced toxic effects compared to R in combination with high-dose dexamethasone in NDMM (Lancet Oncol 2010;11(1):29).
- **Study objective:** To determine the efficacy and safety of R in combination with low-dose dexamethasone (Rd) compared to MPT in transplant-ineligible patients with NDMM.


Phase III FIRST Trial Design

**Eligibility (n = 1,623)**
- Symptomatic NDMM
- Transplant ineligible or ≥65 years old
- Renal impairment allowed, but patients requiring dialysis excluded

**Randomization (1:1:1**
- R: 25 mg d1-21, every 4 weeks
- d: 40 mg d1, 8, 15, 22, every 4 weeks
- M: 0.25 mg/kg d1-4, every 6 weeks
- P: 2 mg/kg d1-4, every 6 weeks
- T: 200 mg d1-42, every 6 weeks

**Primary endpoint:** PFS

- Patients were stratified by age, country and ISS stage.

**PFS: Intention-to-Treat (ITT) Population**

- **Median PFS**
  - Rd (n = 535) 25.5 mos
  - Rd18 (n = 541) 20.7 mos
  - MPT (n = 547) 21.2 mos

**Hazard ratio**
- Rd vs. MPT: 0.72; p = 0.00006
- Rd vs. Rd18: 0.70; p = 0.00001
- Rd18 vs. MPT: 1.03; p = 0.70349

With permission from Facon T et al. *Proc ASH 2013;Abstract 2.*

---

**PFS According to Subgroup**

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Hazard ratio (HR) and 95% CI</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt; 75</td>
<td>0.81 (0.62 - 1.05)</td>
<td>0.62 - 1.05</td>
</tr>
<tr>
<td>Age ≤ 75</td>
<td>0.68 (0.56 - 0.83)</td>
<td>0.56 - 0.83</td>
</tr>
<tr>
<td>Gender: female</td>
<td>0.73 (0.58 - 0.93)</td>
<td>0.58 - 0.93</td>
</tr>
<tr>
<td>Gender: male</td>
<td>0.71 (0.57 - 0.88)</td>
<td>0.57 - 0.88</td>
</tr>
<tr>
<td>Asia</td>
<td>0.61 (0.33 - 1.14)</td>
<td>0.33 - 1.14</td>
</tr>
<tr>
<td>Europe</td>
<td>0.77 (0.63 - 0.93)</td>
<td>0.63 - 0.93</td>
</tr>
<tr>
<td>North America and Pacific</td>
<td>0.64 (0.46 - 0.89)</td>
<td>0.46 - 0.89</td>
</tr>
<tr>
<td>ISS stage: I or II</td>
<td>0.70 (0.57 - 0.87)</td>
<td>0.57 - 0.87</td>
</tr>
<tr>
<td>ISS stage: III</td>
<td>0.75 (0.59 - 0.95)</td>
<td>0.59 - 0.95</td>
</tr>
<tr>
<td>CrCl &lt; 30 ml/min</td>
<td>0.76 (0.44 - 1.30)</td>
<td>0.44 - 1.30</td>
</tr>
<tr>
<td>CrCl 30 - 50 ml/min</td>
<td>0.66 (0.48 - 0.91)</td>
<td>0.48 - 0.91</td>
</tr>
<tr>
<td>CrCl 50 - 80 ml/min</td>
<td>0.74 (0.58 - 0.95)</td>
<td>0.58 - 0.95</td>
</tr>
<tr>
<td>CrCl ≥ 80 ml/min</td>
<td>0.71 (0.51 - 1.01)</td>
<td>0.51 - 1.01</td>
</tr>
<tr>
<td>ECOG PS Grade 0</td>
<td>0.54 (0.39 - 0.74)</td>
<td>0.39 - 0.74</td>
</tr>
<tr>
<td>ECOG PS Grade 1</td>
<td>0.81 (0.65 - 1.01)</td>
<td>0.65 - 1.01</td>
</tr>
<tr>
<td>ECOG PS Grade 2</td>
<td>0.80 (0.57 - 1.12)</td>
<td>0.57 - 1.12</td>
</tr>
<tr>
<td>LDH &lt; 200 IU/l</td>
<td>0.69 (0.58 - 0.83)</td>
<td>0.58 - 0.83</td>
</tr>
<tr>
<td>LDH ≥ 200 IU/l</td>
<td>0.96 (0.66 - 1.39)</td>
<td>0.66 - 1.39</td>
</tr>
<tr>
<td>Cytogenetics High-risk</td>
<td>1.23 (0.78 - 1.93)</td>
<td>0.78 - 1.93</td>
</tr>
<tr>
<td>Cytogenetics Non-high Risk</td>
<td>0.69 (0.53 - 0.90)</td>
<td>0.53 - 0.90</td>
</tr>
</tbody>
</table>

**ITT patients**
0.72 (0.61 - 0.85)

With permission from Facon T et al. *Proc ASH 2013;Abstract 2.*
Time to Progression and Time to Second Antimyeloma Therapy (AMT)

Time to Progression

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Median TTP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rd</td>
<td>32.5 mos</td>
</tr>
<tr>
<td>Rd18</td>
<td>21.9 mos</td>
</tr>
<tr>
<td>MPT</td>
<td>23.9 mos</td>
</tr>
</tbody>
</table>

Hazard ratio
- Rd vs. MPT: 0.68; p = 0.00001
- Rd vs. Rd18: 0.62; p ≤ 0.00001
- Rd18 vs. MPT: 1.11; p = 0.21718

Time to 2nd AMT

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Median Time to 2nd AMT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rd</td>
<td>39.1 mos</td>
</tr>
<tr>
<td>Rd18</td>
<td>28.5 mos</td>
</tr>
<tr>
<td>MPT</td>
<td>26.7 mos</td>
</tr>
</tbody>
</table>

Hazard ratio
- Rd vs. MPT: 0.66; p < 0.00001
- Rd vs. Rd18: 0.74; p = 0.000067
- Rd18 vs. MPT: 0.88; p = 0.12333

With permission from Facon T et al. Proc ASH 2013;Abstract 2.

Interim Analysis of OS

574 deaths (35% of ITT)

<table>
<thead>
<tr>
<th>Therapy</th>
<th>4-year OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rd</td>
<td>59.4%</td>
</tr>
<tr>
<td>Rd18</td>
<td>55.7%</td>
</tr>
<tr>
<td>MPT</td>
<td>51.4%</td>
</tr>
</tbody>
</table>

Hazard ratio
- Rd vs. MPT: 0.78; p = 0.0168
- Rd vs. Rd18: 0.90; p = 0.307
- Rd18 vs. MPT: 0.88; p = 0.184

With permission from Facon T et al. Proc ASH 2013;Abstract 2.
## Response Rates

<table>
<thead>
<tr>
<th>Response</th>
<th>Continuous Rd (n = 535)</th>
<th>Rd18 (n = 541)</th>
<th>MPT (n = 547)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall response rate</td>
<td>75.1%</td>
<td>73.4%</td>
<td>62.3%</td>
</tr>
<tr>
<td>Complete response</td>
<td>15.1%</td>
<td>14.2%</td>
<td>9.3%</td>
</tr>
<tr>
<td>Very good partial response</td>
<td>28.4%</td>
<td>28.5%</td>
<td>18.8%</td>
</tr>
<tr>
<td>Partial response</td>
<td>31.6%</td>
<td>30.7%</td>
<td>34.2%</td>
</tr>
<tr>
<td>Stable disease</td>
<td>18.9%</td>
<td>20.5%</td>
<td>26.5%</td>
</tr>
</tbody>
</table>

- Time to response: 1.8 mo (continuous Rd); 1.8 mo (Rd18); 2.8 mo (MPT)
- Duration of response: 35.0 mo (continuous Rd); 22.1 mo (Rd18); 22.3 mo (MPT)


## Select Adverse Events

<table>
<thead>
<tr>
<th>Grade 3/4</th>
<th>Continuous Rd (n = 532)</th>
<th>Rd18 (n = 540)</th>
<th>MPT (n = 541)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>18.2%</td>
<td>15.7%</td>
<td>18.9%</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>27.8%</td>
<td>26.5%</td>
<td>44.9%</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>8.3%</td>
<td>8.0%</td>
<td>11.1%</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>1.1%</td>
<td>3.0%</td>
<td>2.6%</td>
</tr>
<tr>
<td>Infections</td>
<td>28.9%</td>
<td>21.9%</td>
<td>17.2%</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>8.1%</td>
<td>8.3%</td>
<td>5.7%</td>
</tr>
<tr>
<td>DVT and/or PE</td>
<td>7.9%</td>
<td>5.6%</td>
<td>5.4%</td>
</tr>
<tr>
<td>Cataract</td>
<td>5.8%</td>
<td>2.6%</td>
<td>0.6%</td>
</tr>
</tbody>
</table>

DVT = deep vein thrombosis; PE = pulmonary embolism

Incidence of Second Primary Malignancy (SPM)

<table>
<thead>
<tr>
<th>Malignancy, n (%)</th>
<th>Continuous Rd (n = 532)</th>
<th>Rd18 (n = 540)</th>
<th>MPT (n = 541)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML</td>
<td>1 (0.2%)</td>
<td>1 (0.2%)</td>
<td>4 (0.7%)</td>
</tr>
<tr>
<td>MDS</td>
<td>1 (0.2%)</td>
<td>1 (0.2%)</td>
<td>6 (1.1%)</td>
</tr>
<tr>
<td>MDS to AML</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>2 (0.4%)</td>
</tr>
<tr>
<td>B-cell</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Solid tumors</td>
<td>15 (2.8%)</td>
<td>29 (5.4%)</td>
<td>15 (2.8%)</td>
</tr>
<tr>
<td>Invasive SPM</td>
<td>17 (3.2%)</td>
<td>30 (5.6%)</td>
<td>27 (5.0%)</td>
</tr>
<tr>
<td>Pts with ≥1 noninvasive, nonmyeloma skin cancer</td>
<td>22 (4.1%)</td>
<td>17 (3.1%)</td>
<td>21 (3.9%)</td>
</tr>
</tbody>
</table>

AML = acute myeloid leukemia; MDS = myelodysplastic syndromes


Author Conclusions

- Continuous administration of Rd significantly extended PFS, with an OS benefit in comparison to MPT.
  - PFS results:
    - Hazard ratio = 0.72; \(p = 0.00006\)
    - Consistent benefit across most patient subgroups
    - Continuous Rd was better than Rd18
      - Hazard ratio = 0.70; \(p = 0.00001\)
  - Planned interim OS results:
    - Hazard ratio = 0.78; \(p = 0.0168\)
    - Rd was superior to MPT across all efficacy secondary endpoints.
- The safety profile with continuous Rd was manageable.
- In transplant-ineligible patients with NDMM, the FIRST trial establishes continuous Rd as a new standard.

FIRST: A Phase III Trial of Continuous Rd versus Rd18 versus MPT for Patients with NDMM

Two questions were being asked: Is Rd better than MPT, and does continuous therapy improve the benefit of Rd over MPT? In terms of PFS, OS and time to second antimonyeloma therapy, continuous Rd is clearly the winner. The time to progression (TTP) curve is similar for MPT and Rd when they are administered for equal durations. The SPM rate was lower with continuous Rd than in the other 2 groups. These data support the importance of continuous therapy in multiple myeloma whether patients are older, as in this trial, or younger, as in the post-transplant period. In terms of OS, it is important that continuous Rd was statistically different from MPT but not from Rd18. The difference in TTP between continuous Rd and Rd18 is big. I believe that the only way for a big OS difference to occur in an induction trial is if 1 of the arms is inferior, because patients are living so long.

We probably don’t have enough follow-up yet to see a difference in survival between continuous Rd and Rd18. Clearly Rd is better than MPT, and one wouldn’t administer MPT for longer than the duration used in this trial. The biggest issue regarding this study is that few US physicians administer MPT. It’s hard to understand what the extrapolation of this data is for similar patients in the United States.

*Interview with Sagar Lonial, MD, January 22, 2014*